Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(50.0%)
Phase 2
1(25.0%)
N/A
1(25.0%)
4Total
Phase 4(2)
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02992704Phase 2Completed

Peg-interferon for Inactive Chronic Hepatitis B Carriers

Role: lead

NCT04102176Not ApplicableActive Not Recruiting

Halting Nucleoside Analogues in Chronic Hepatitis B

Role: lead

NCT01928511Phase 4Completed

Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy

Role: lead

NCT02774837Phase 4Unknown

Tenofovir Versus Tenofovir + Telbivudine for Chronic Hepatitis B

Role: lead

All 4 trials loaded